Novo Nordisk has acquired two small Indiana based research Biotechs, Calibrium and MB2, as part of its strategy to establish itself in the US as a major Diabetes research giant.
Novo Nordisk, a global endocrine research giant hailing from Copenhagen, Denmark, has plans to acquire two smaller, privately held research companies into its conglomeration. Focusing on research in diabetes and other metabolic disorders, the two companies in question, Calibrium and MB2, are currently based in Indiana (US) and have only recently been founded in 2013 and 2014.
Despite Novo’s recent set-back regarding Liraglutide’s failure to get through Phase III trials for Diabetes Type treatment, the Novo-morale continues to be optimistic. According to Novo’s executive Vice-President, Mags Krogsgaard Thomsen, the move to absorb these small US biotechs is being described as a great opportunity to add to Novo’s intellectual property. He was also highly praising of Richard DeMarchi, CEO of Calibrium and also CSO of MB2, stating “This research team has demonstrated world-class capabilities in protein design and created a project portfolio of innovative product leads that fits very well with our aspirations within diabetes and obesity”.